On May 2 Joyce A Lonergan Filed SEC Form. Mellitus $5.59 million Financing.

May 3, 2018 - By Heather Owens

Mellitus Fundraising

A form D was filed by Mellitus, Llc, Limited Liability Company for $5.59 million equity financing. This is a new filing. Mellitus sold $5.59 million or 100.00 % of the financing round.In total it’s $5.59 million. On 2018-05-02 the document was filed and the reason was: unspecified.

Mellitus is based in Massachusetts. The filler works in the Biotechnology business. The person that filed the form was Joyce A Lonergan Chief Executive Officer & Co-Founder. The company was incorporated more than five years ago. The filler’s address is: Cic Boston, 16Th Floor, 50 Milk Street, Boston, Ma, Massachusetts, 02109. Joyce A. Lonergan is the related person in the form and it has address: C/O Mellitus, Llc, Cic Boston, 16Th Floor, 50 Milk Street, Boston, Ma, Massachusetts, 02109. Link to Mellitus Filing: 000158830118000001.

Mellitus Offering Details

The firms in the Biotechnology sector sell on avg 73.77 % of their offerings size. Mellitus have sold 100.00 % so far. Could this mean that the trust in Mellitus is high? Also companies in the Biotechnology industry have an avg fundraising size of $3.08 million.And the total raised amount is 81.61 % bigger than the average.As for minimum investment it was required at $0.

Form D – advantages and disadvantages

Usually Form D fillings have information that ventures and startups don’t like revealing. More precisely they reveal plans and reasons for funds raising. On other hand this could help understand better your competitors.

Mellitus ‘s pluses of Fundraising Reporting

The Form D signed by Joyce A Lonergan might help Mellitus, Llc as clients feel much more safe to work with a better financed firm. Chances are high that Mellitus, Llc will stay financially sound. There are good PR effects as well as more attention from angels venture-capital, firms and funds.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: